Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Kronos Bio ( (KRON) ) has shared an update.
Kronos Bio, Inc. has entered into a Transition Agreement with Genentech, Inc. and F. Hoffmann-La Roche Ltd to terminate their previous Collaboration and License Agreement. As part of the agreement, Kronos Bio will transfer all small molecule compounds, materials, data, and intellectual property from their joint research programs to Genentech, while retaining its proprietary drug discovery platform. This transition includes a perpetual license for Genentech and cancels any downstream payment obligations between the parties, alongside a one-time payment from Kronos Bio to support the transition.
More about Kronos Bio
Kronos Bio, Inc. is a biotechnology company that focuses on the discovery and development of novel cancer therapies using its proprietary drug discovery platform.
YTD Price Performance: -26.40%
Average Trading Volume: 225,041
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $55.51M
For an in-depth examination of KRON stock, go to TipRanks’ Stock Analysis page.
Trending Articles
- ‘Keep On Buying,’ Says Investor About Microsoft Stock
- ‘Priced for Fantasy,’ Says Investor About Tesla Stock
- ‘Remain Skeptical,’ Says Top Investor About AMD Stock
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
